Key points are not available for this paper at this time.
The ADs to organs at risk obtained with the new workstation PLANET® Dose are concordant with those calculated with the currently used software and in agreement with the literature. These results validate the use of PLANET® Dose in clinical routine for patient dosimetry after targeted radiotherapy with 177LuLu-DOTA-TATE.
Santoro et al. (Mon,) studied this question.